Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04850950
Other study ID # 2021-KY-0144-002
Secondary ID
Status Not yet recruiting
Phase Phase 4
First received
Last updated
Start date April 26, 2021
Est. completion date December 31, 2022

Study information

Verified date April 2021
Source The First Affiliated Hospital of Zhengzhou University
Contact Qing-Lei Zeng, M.D.
Phone 86 15838120512
Email zengqinglei2009@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To investigate the safety and efficacy of tenofovir alafenamide (orally 25 mg per day) treated in inactive chronic hepatitis B virus (HBV)-infected pregnant women with high viral load from the late pregnancy until the delivery date or postpartum 1 month.


Description:

The investigators intend to include 240 inactive chronic hepatitis B virus (HBV)-infected pregnant women who have an HBV DNA level higher than 200,000 IU per milliliter. Participants will be randomly assigned, in a 1:1 ratio, to receive tenofovir alafenamide (orally 25 mg per day) from the late pregnancy until the delivery date or postpartum 1 month. All the infants will receive standard immunoprophylaxis (100 IU of hepatitis B immunoglobulin and 10 μg of hepatitis B vaccine within 12 hours of birth; the second injection of 10 μg of HBV vaccine will inject at 1 month; and the third dose of 10 μg of HBV vaccine will give at 6 months). The pregnant women and their infants will be followed until postpartum month 7. The primary outcomes are the birth defects and rates of perinatal transmission of HBV. During the prenatal period or the postnatal period up to 7 months of age, cases of a structural defect in newborns or infants were reported as birth defects. The rate of perinatal transmission was defined as the proportion of infants who are positive for hepatitis B surface antigen at 7 months of age. The secondary safety outcomes are the occurrence of maternal or infant adverse events during the study period. Maternal safety evaluations mainly include any adverse events and complications, hepatitis B virologic breakthrough, alanine aminotransferase flare, and so on. Infant' safety profiles mainly included Apgar scores at 1 minute, any abnormal conditions during the study period, and anthropometric indexes at birth and 7 months of age. The secondary efficacy outcomes are the percentages of mothers with an HBV DNA level of less than 200,000 IU per milliliter just before or at delivery, and the hepatitis B e antigen and surface antigen loss or seroconversion in mothers at postpartum month 7.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 240
Est. completion date December 31, 2022
Est. primary completion date December 31, 2022
Accepts healthy volunteers No
Gender Female
Age group 20 Years to 40 Years
Eligibility Inclusion Criteria: 1. Gestational age of more than 30 weeks; 2. Had chronic hepatitis B virus (HBV) infection; 3. HBV DNA > 200,000 IU/ml; 4. Consecutively normal levels of alanine aminotransferase (< 40 U/L) and total bilirubin (< 17.1 µmol/L); 5. Willing and able to provide written informed consent and adhere to the trial protocol. Exclusion Criteria: 1. Previous treatment to reduce alanine aminotransferase and total bilirubin levels; 2. Previous antiviral treatment for HBV infection (except when antiviral agents were administered for the prevention of perinatal transmission during a previous pregnancy and discontinued more than 6 months before the current pregnancy); 3. Coinfection with hepatitis C, D, E, or human immunodeficiency virus; 4. Previous or current evidence of hepatocellular carcinoma, cirrhosis, systemic or other organ disorders; 5. A hemoglobin level of less than 80 g/L; 6. A neutrophil count of less than 1.0 × 10^9/L; 7. An albumin level of less than 30 g/L; 8. Clinical signs of threatened miscarriage; 9. Evidence of fetal deformity by ultrasound examination and other tests; 10. A history of abortion, pregnancy loss, or congenital malformation in a previous pregnancy; 11. A history of genetic disease(s), including the family member(s); 12. Concurrent treatment with other drugs, including but not limited to nephrotoxic drugs, immune modulators, cytotoxic drugs, nonsteroidal antiinflammatory drugs, or steroids.

Study Design


Intervention

Drug:
Tenofovir Alafenamide fumarate 25mg Oral Tablet
Tenofovir alafenamide fumarate initiated from the late pregnancy to the delivery date or postpartum month 1.

Locations

Country Name City State
n/a

Sponsors (15)

Lead Sponsor Collaborator
The First Affiliated Hospital of Zhengzhou University Fifth People's Hospital of Anyang, First Affiliated Hospital of Nanyang Medical College, Henan Provincial People's Hospital, Luohe Central Hospital, Luoyang Central Hospital, Nanyang Central Hospital, National Natural Science Foundation of China, Second Affiliated Hospital of Xi'an Jiaotong University, Shandong Provincial Hospital, Sixth People's Hospital of Kaifeng, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, The Sixth People's Hospital of Zhengzhou, Xinyang Central Hospital, Yan'an University Affiliated Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary Birth defects. Structural defect in newborns or infants were reported as birth defects. The monitoring of birth defects was conducted by a clinical examination during each visit, and further clinical imaging or other tests were performed if indicated. The birth defect rate represented the proportion of infants with a defect among all live births. From prenatal tenofovir alafenamide exposure to the birth and postnatal period up to 7 months of age.
Primary The rate of perinatal transmission of hepatitis B virus. The rate of perinatal transmission was defined as the proportion of infants who are positive for hepatitis B surface antigen at 7 months of age. At 7 months of age.
Secondary Adverse events. The occurrence of any maternal or infant adverse events. From prenatal tenofovir alafenamide exposure to the delivery (birth) and postnatal period up to 7 months (of age).
Secondary Alanine aminotransferase flare. Alanine aminotransferase flare was defined as a level greater than 5 or 10 times the upper limit of normal, which was set as 40 U/L according to the Asian-Pacific chronic hepatitis B guideline. At postpartum month 7.
Secondary Infants' growth. Infant growth was measured by the WHO z scores for age for weight, height, and head circumference. At birth and 7 months of age.
Secondary HBV DNA level. Percentage of HBV DNA level of less than 200,000 IU per milliliter for mothers. Immediately before or at delivery.
Secondary Hepatitis B e antigen status. Percentage of hepatitis B e antigen loss or seroconversion for mothers. At postpartum month 7.
Secondary Hepatitis B surface antigen status. Percentage of hepatitis B surface antigen loss or seroconversion for mothers. At postpartum month 7.
See also
  Status Clinical Trial Phase
Recruiting NCT04496882 - Chronic Hepatitis b Patients Switch to tAf After Discontinuation of Nucleoside Analogue Phase 4
Completed NCT04083716 - A Study to Assess the Relative Bioavailability and Food Effect of ABI-H2158 in Healthy Adults Phase 1
Not yet recruiting NCT03038802 - A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection Phase 1/Phase 2
Completed NCT05310487 - Phase 1 Study of 162, a Novel Neutralizing Antibody Targeting Hepatitis B Surface Antigen, in Healthy Adult Subjects Phase 1
Recruiting NCT06070051 - Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy Phase 1
Terminated NCT05001022 - A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects Phase 1
Recruiting NCT04139850 - The Establishment of Korean Hepatitis B Patients Cohort
Recruiting NCT05343481 - Efficacy of VTP-300 in Chronic Hepatitis B Infection Phase 2
Not yet recruiting NCT05490836 - Functional Cure Rate of Peg-IFNα-2b Combined With TAF in HBeAg Negative CHB Patients N/A
Recruiting NCT04543565 - Pradefovir Treatment for the Patients With Chronic Hepatitis B Virus Infections: a Phase3 Study Phase 3
Active, not recruiting NCT02894918 - A Study to Evaluate Addition of Peginterferon Alfa-2a to Chronic Hepatitis B (CHB) Patients Treated With NAs Phase 4
Not yet recruiting NCT02793791 - Prophylactic Treatment of Hepatic Dysplastic Nodules in HBsAg Positive Patients N/A
Recruiting NCT02287857 - Efficacy and Safety of Domestic Tenofovir Tablets in Chinese Patients With Chronic Hepatitis B N/A
Recruiting NCT01965418 - A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial Phase 4
Recruiting NCT01491295 - Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients Phase 4
Terminated NCT01872988 - Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related Hepatocellular Carcinoma Phase 3
Recruiting NCT01487876 - Efficacy and Safety of Dual-plasmid Hepatitis B Virus DNA Vaccine in Chronic Hepatitis B Patients Phase 2
Completed NCT01531166 - A Cohort Study in Korean Patients With Chronic Hepatitis B (CHB) Receiving Pegylated Interferon N/A
Not yet recruiting NCT01436539 - Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients Phase 4
Recruiting NCT01360879 - Assessment of Liver FIBROsis by Real-time Tissue ELASTography in Chronic Liver Disease N/A